Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Transition from intravenous epoprostenol to selexipag in pulmonary arterial hypertension: a word of caution

Kenichi Yanaka, Alicia Guillien, Thibaud Soumagne, Justin Benet, Nicolas Piliero, François Picard, Christophe Pison, Olivier Sitbon, Hélène Bouvaist, Bruno Degano
European Respiratory Journal 2020 55: 1902418; DOI: 10.1183/13993003.02418-2019
Kenichi Yanaka
1Dept of Cardiology, Grenoble Alpes University Hospital, Grenoble, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alicia Guillien
2Environmental Epidemiology applied to Reproduction and Respiratory Health, INSERM, CNRS, University Grenoble Alpes, Institute for Advanced Biosciences (IAB), U1209 Joint Research Center, Grenoble, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thibaud Soumagne
3Dept of Intensive Care Medicine, University Hospital, Besançon, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Justin Benet
4Dept of Respiratory Medicine, University Hospital of Grenoble Alpes, Grenoble, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicolas Piliero
1Dept of Cardiology, Grenoble Alpes University Hospital, Grenoble, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
François Picard
5Dept of Cardiology, Haut-Lévêque, Pessac, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christophe Pison
4Dept of Respiratory Medicine, University Hospital of Grenoble Alpes, Grenoble, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olivier Sitbon
6University Paris-Saclay, Le Kremlin-Bicêtre, France
7Dept of Respiratory Medicine, Bicêtre Hospital, AP-HP, Le Kremlin-Bicêtre, France
8INSERM, UMR_S999, Le Plessis-Robinson, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Olivier Sitbon
Hélène Bouvaist
1Dept of Cardiology, Grenoble Alpes University Hospital, Grenoble, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bruno Degano
4Dept of Respiratory Medicine, University Hospital of Grenoble Alpes, Grenoble, France
9HP2 Laboratory, INSERM U1042, University Grenoble Alpes, Grenoble, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: bdegano@chu-grenoble.fr
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Even for patients who are very stable while receiving i.v. epoprostenol over a long period of time, any transition to selexipag warrants careful long-term clinical and haemodynamic follow-up because worsening is likely to occur http://bit.ly/32wR9eX

To the Editor:

Prostacyclin analogues targeting the prostacyclin pathway are used to treat patients with pulmonary arterial hypertension (PAH), and are given either by an intravenous, subcutaneous or inhaled route [1]. Continuous i.v. infusion of epoprostenol has received the strongest recommendation for treatment of the most severe forms of PAH [2], mainly because it is the only PAH-specific drug that was demonstrated to give an improvement in survival in a randomised controlled study [3]. Due to drawbacks associated with its i.v. administration, epoprostenol is preferentially offered to young, high-risk patients [2]. For PAH patients in New York Heart Association (NYHA) functional class (FC) III/IV with severe haemodynamic impairment, epoprostenol can be combined with an endothelin receptor antagonist (ERA) and a phosphodiesterase type-5 (PDE-5) inhibitor to achieve sustained clinical and haemodynamic efficacy [4, 5].

Selexipag is a prostacyclin receptor agonist whose molecular structure is different from the prostacyclin analogues that can be orally administered with few side-effects [6, 7]. Therefore, while selexipag has been developed for the treatment of PAH, it is not considered equivalent to prostacyclin analogues [1, 2]. Nevertheless, due to recurrent catheter-related infections and/or problems with patient acceptance, several physicians have attempted to replace i.v. epoprostenol with selexipag in selected patients. The current literature provides some reports and case-series of successful transitions from a prostacyclin analogue to selexipag. The available data are, however, fragmentary because of 1) the small number of cases; 2) the type of drug administered before the transition (mainly treprostinil (i.v. or s.c.) or inhaled prostacyclin); and 3) the absence of long-term haemodynamic follow-up. As not all prostacyclin analogues and/or all routes of administration are equivalent for the treatment of PAH [1], we aimed to investigate the consequences of transition from i.v. epoprostenol to oral selexipag.

The study population consisted of all patients with PAH enrolled in the French PH Network registry treated for at least 3 months with i.v. epoprostenol, who have been transitioned to oral selexipag, and with at least one evaluation, including a right heart catheterisation, while on selexipag. Clinical and haemodynamic characteristics of patients were collected at the time of first diagnosis of PAH, at the time of transition (while receiving epoprostenol, just before the initiation of selexipag), and at first and last evaluations on selexipag. Continuous variables were compared using a Wilcoxon signed-ranked test and categorical variables were compared using a McNemar test or a cumulative logic marginal model for variables with two categories and three or more categories, respectively [8]. A Bonferroni correction was applied to correct for multiple tests and, thus, a p-value lower than 0.025 was considered as significant.

We identified eight patients with PAH (idiopathic, n=5; heritable, n=2; associated with a connective tissue disease, n=1) who were transitioned from i.v. epoprostenol to oral selexipag between September 2016 and January 2019 (six females; median age 39.4 (interquartile range (IQR) 34.1–52.7) years). All had a severe form of PAH at the time of diagnosis (figure 1).

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

Individual clinical and haemodynamic characteristics of eight patients with severe pulmonary arterial hypertension (PAH) at diagnosis. Measurements at “diagnosis” were performed without any PAH treatment and measurements at “transition” in patients receiving a stable dose of intravenous epoprostenol. “First evaluations” were performed in patients receiving selexipag for a median (interquartile range) duration of 4.4 (4.0–6.3) months (n=8) and “last evaluations” in patients receiving selexipag for 17.8 (6.1–25.9) months (n=7). a) Number of low-risk criteria met according to the French registry invasive method, the four criteria being 1) New York Heart Association (NYHA) functional class (FC); 2) 6-min walk distance (6MWD); 3) right atrial pressure (RAP); and 4) cardiac index. b) Number of low-risk criteria met according to French registry non-invasive method, i.e. 1) NYHA FC; 2) brain natriuretic peptide (BNP)/N-terminal pro-BNP (NT-proBNP); and 3) 6MWD. c) Risk stratification according to the SPAHR/COMPERA method, that grades 6MWD, NYHA FC, NT-proBNP, RAP, cardiac index and mixed venous oxygen saturation from 1 to 3 (1, low; 2, intermediate; 3, high) using the European Society of Cardiology/European Respiratory Society risk thresholds. d) NYHA FC. e–h) Individual values of RAP, mean pulmonary artery pressure (mPAP), cardiac index and pulmonary vascular resistance (PVR). The black lines indicate median values.

At the time of transition, patients had been receiving i.v. epoprostenol for a median (IQR) 5.1 (2.0–8.3) years. The median (IQR) dose of epoprostenol was 17.5 (15.0–29.5) ng·kg−1·min−1. All patients were also receiving an ERA and a PDE-5 inhibitor in combination with i.v. epoprostenol. They were all in stable condition and most were at “low risk” according to the French invasive and non-invasive approaches and the SPAHR/COMPERA method (figure 1) [9–11]. Transition was decided either because of the patient's refusal to continue i.v. epoprostenol (n=2) or due to recurrent catheter-related infections (n=6). In all cases, selexipag dosage was uptitrated from 200 μg b.i.d. to the maximal tolerated dose stepwise over 2 to 5 days, while parallel perfusion of epoprostenol was tapered off. The transition was well-tolerated in all cases. After transition and during follow-up, patients still received an ERA and a PDE-5 inhibitor together with a stable dose of selexipag (1600 µg b.i.d. in all cases).

At the first evaluation on selexipag (4.4 (4.0–6.3) months after transition), NYHA FC and risk stratification (SPAHR/COMPERA method) did not change, but the risk assessment according to both French methods had significantly worsened compared with before transition (p-values of 0.024 and 0.023 for the invasive and non-invasive methods, respectively) (figure 1). In the meantime, 6-min walk distance (6MWD) and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) remained remarkably stable (from 546 (412–555) to 526 (379–586) m and from 190 (136–354) to 224 (152–598) ng·L−1, respectively) but the cardiac index significantly decreased (p=0.016). The worsening of the French risk scores was mainly driven by a deterioration in cardiac index and in right atrial pressure (figure 1). At final evaluation on selexipag (17.8 (6.1–25.9) months after transition), 6MWD and NT-proBNP remained stable compared with the first evaluation (526 (304–619) m and 282 (142–813) ng·L−1, respectively). There was, however, a trend towards a further deterioration in risk and in cardiac index (p-values of 0.070, 0.046 and 0.049 for the French invasive, French non-invasive method and cardiac index, respectively) (figure 1). Between transition and last evaluation on selexipag, mixed venous oxygen saturation did not change significantly (from 73% (70–78%) to 68% (67–68%)) despite the deterioration in cardiac index, and in the meantime serum haemoglobin increased by 2 g·dL−1.

To date, Frost et al. [12] have reported the largest series of patients (n=34) undergoing transition from a prostacyclin analogue (treprostinil) administered by inhalation. Overall, patients in the series of Frost et al. [12] remained stable throughout the 16-week treatment, but only clinical end-points were evaluated. In addition, as patients were long-term survivors (time from diagnosis close to 8 years, with a risk of a survivor bias), the follow-up of only 16 weeks was possibly too short to detect any decline.

Another series of four cases of transition from i.v. or s.c. treprostinil to selexipag has been reported. Transitions were considered successful but, unfortunately, only patients' conditions at transition were given, without any follow-up data [13]. These data are therefore of poor added value. Recently, Holthaus et al. [14] reported a series of five patients with severe PAH at diagnosis. All were stable with a NYHA FC I/II while receiving i.v. treprostinil when they were transitioned to selexipag. Transition was well tolerated, with no significant short-term changes in NYHA FC. However, in line with our findings, there was a trend towards a reduction in cardiac index as early as 3–6 months after transition to selexipag, suggesting a poorer haemodynamic effect of selexipag than of i.v. treprostinil, but no long-term data were provided [14].

According to both our findings and the available literature, we suggest that some previous conclusions reporting stability after transition should be reconsidered, for at least two reasons. First, clinical criteria (such as 6MWD) may appear stable (as is the case in our series) while in the meantime, haemodynamic parameters (such as cardiac index) significantly worsen. Second, stability might be observed for transitions from less efficient forms of prostacyclin analogue treatments (i.e. inhaled administration) while significant deterioration is likely to occur for a transition from the most efficient treatment (i.e. i.v. epoprostenol). We therefore consider there is a need for a word of caution: even for patients who are very stable while receiving a given prostacyclin analogue (especially i.v. epoprostenol) over a long period of time, any transition to selexipag warrants careful long-term clinical and haemodynamic follow-up, because worsening is likely to occur. Such a transition should be restricted to patients unable to pursue epoprostenol for medical reasons, and only after a collegiate discussion. As far as possible, never change a winning team!

Shareable PDF

Supplementary Material

This one-page PDF can be shared freely online.

Shareable PDF ERJ-02418-2019.Shareable

Footnotes

  • Conflict of interest: K. Yanaka has nothing to disclose.

  • Conflict of interest: A. Guillien has nothing to disclose.

  • Conflict of interest: T. Soumagne has nothing to disclose.

  • Conflict of interest: J. Benet has nothing to disclose.

  • Conflict of interest: N. Piliero has nothing to disclose.

  • Conflict of interest: F. Picard has nothing to disclose.

  • Conflict of interest: C. Pison reports grants and personal fees from GlaxoSmithKline, personal fees from Novartis Pharma, Boehringer Ingelheim and AstraZeneca, outside the submitted work.

  • Conflict of interest: O. Sitbon reports personal fees from Arena Pharmaceuticals, Acceleron Pharmaceuticals and Gossamer Bio, personal fees and non-financial support from Actelion Pharmaceuticals, grants and personal fees from Bayer HealthCare and Merck, non-financial support from GlaxoSmithKline, outside the submitted work.

  • Conflict of interest: H. Bouvaist reports grants and non-financial support from GlaxoSmithKline and Bayer HealthCare, personal fees and non-financial support from Actelion Pharmaceuticals, outside the submitted work.

  • Conflict of interest: B. Degano reports personal fees and non-financial support from Actelion Pharmaceuticals, non-financial support from Bayer HealthCare, grants, personal fees and non-financial support from Novartis Pharma, personal fees from Chiesi, GlaxoSmithKline and Menarini, outside the submitted work.

  • Received December 16, 2019.
  • Accepted February 16, 2020.
  • Copyright ©ERS 2020
https://www.ersjournals.com/user-licence

References

  1. ↵
    1. Barnes H,
    2. Yeoh HL,
    3. Fothergill T, et al.
    Prostacyclin for pulmonary arterial hypertension. Cochrane Database Syst Rev 2019; 5: CD012785.
    OpenUrl
  2. ↵
    1. Galie N,
    2. Channick RN,
    3. Frantz RP, et al.
    Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J 2019; 53: 1801889.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Barst RJ,
    2. Rubin LJ,
    3. Long WA, et al.
    A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334: 296–301. doi:10.1056/NEJM199602013340504
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. D'Alto M,
    2. Badagliacca R,
    3. Argiento P, et al.
    Risk reduction and right heart reverse remodeling by upfront triple combination therapy in pulmonary arterial hypertension. Chest 2020; 157: 376–383.
    OpenUrl
  5. ↵
    1. Sitbon O,
    2. Jais X,
    3. Savale L, et al.
    Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J 2014; 43: 1691–1697. doi:10.1183/09031936.00116313
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Sitbon O,
    2. Channick R,
    3. Chin KM, et al.
    Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 2015; 373: 2522–2533. doi:10.1056/NEJMoa1503184
    OpenUrlCrossRefPubMed
  7. ↵
    1. Simonneau G,
    2. Torbicki A,
    3. Hoeper MM, et al.
    Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J 2012; 40: 874–880. doi:10.1183/09031936.00137511
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Agresti A
    . An Introduction to Categorical Data Analysis. 3rd Edn. Hoboken, John Wiley and Sons, 2018.
  9. ↵
    1. Boucly A,
    2. Weatherald J,
    3. Savale L, et al.
    Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J 2017; 50: 1700889.
    OpenUrlAbstract/FREE Full Text
    1. Hoeper MM,
    2. Kramer T,
    3. Pan Z, et al.
    Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J 2017; 50: 1700740.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Kylhammar D,
    2. Kjellstrom B,
    3. Hjalmarsson C, et al.
    A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart J 2018; 39: 4175–4181. doi:10.1093/eurheartj/ehx257
    OpenUrl
  11. ↵
    1. Frost A,
    2. Janmohamed M,
    3. Fritz JS, et al.
    Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study. J Heart Lung Transplant 2019; 38: 43–50. doi:10.1016/j.healun.2018.09.003
    OpenUrl
  12. ↵
    1. Fanous SM,
    2. Janmohamed M
    . Transition from treprostinil to selexipag in patients with pulmonary arterial hypertension: case series. Am J Health Syst Pharm 2018; 75: 1877–1881. doi:10.2146/ajhp170814
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Holthaus N,
    2. Prins K,
    3. Rose L, et al.
    EXPRESS: transition from parental prostacyclin to selexipag: a case series of five pulmonary arterial hypertension patients. Pulm Circ 2019; 9: 2045894019862167.
    OpenUrl
PreviousNext
Back to top
View this article with LENS
Vol 55 Issue 6 Table of Contents
European Respiratory Journal: 55 (6)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Transition from intravenous epoprostenol to selexipag in pulmonary arterial hypertension: a word of caution
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Transition from intravenous epoprostenol to selexipag in pulmonary arterial hypertension: a word of caution
Kenichi Yanaka, Alicia Guillien, Thibaud Soumagne, Justin Benet, Nicolas Piliero, François Picard, Christophe Pison, Olivier Sitbon, Hélène Bouvaist, Bruno Degano
European Respiratory Journal Jun 2020, 55 (6) 1902418; DOI: 10.1183/13993003.02418-2019

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Transition from intravenous epoprostenol to selexipag in pulmonary arterial hypertension: a word of caution
Kenichi Yanaka, Alicia Guillien, Thibaud Soumagne, Justin Benet, Nicolas Piliero, François Picard, Christophe Pison, Olivier Sitbon, Hélène Bouvaist, Bruno Degano
European Respiratory Journal Jun 2020, 55 (6) 1902418; DOI: 10.1183/13993003.02418-2019
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Shareable PDF
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Refined risk stratification in PAH and timing of lung transplantation
  • Outcomes of cirrhotic patients with pre-capillary pulmonary hypertension
  • Diagnosis for cystic fibrosis with new generation sweat test
Show more Agora

Research letters

  • Outcomes of cirrhotic patients with pre-capillary pulmonary hypertension
  • Diagnosis for cystic fibrosis with new generation sweat test
  • Association of blood trihalomethane concentrations with lung function
Show more Research letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society